HK1150401A1 - Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy - Google Patents

Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Info

Publication number
HK1150401A1
HK1150401A1 HK11104085.5A HK11104085A HK1150401A1 HK 1150401 A1 HK1150401 A1 HK 1150401A1 HK 11104085 A HK11104085 A HK 11104085A HK 1150401 A1 HK1150401 A1 HK 1150401A1
Authority
HK
Hong Kong
Prior art keywords
oncogenicity
assessment
assay system
tumor progression
treatment efficacy
Prior art date
Application number
HK11104085.5A
Other languages
English (en)
Inventor
Niven Rajin Narain
Indushekhar Persaud
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of HK1150401A1 publication Critical patent/HK1150401A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
HK11104085.5A 2008-01-25 2011-04-21 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy HK1150401A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2357008P 2008-01-25 2008-01-25
PCT/US2009/031957 WO2009094619A1 (en) 2008-01-25 2009-01-26 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Publications (1)

Publication Number Publication Date
HK1150401A1 true HK1150401A1 (en) 2011-12-23

Family

ID=40901454

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11104085.5A HK1150401A1 (en) 2008-01-25 2011-04-21 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Country Status (8)

Country Link
US (1) US10365279B2 (xx)
EP (2) EP2708894B1 (xx)
JP (3) JP2011511271A (xx)
KR (2) KR101711860B1 (xx)
AU (1) AU2009206289A1 (xx)
ES (2) ES2453161T3 (xx)
HK (1) HK1150401A1 (xx)
WO (1) WO2009094619A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
US20220088031A1 (en) * 2019-02-01 2022-03-24 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
KR20040064275A (ko) * 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
FR2840923B1 (fr) * 2002-06-17 2007-07-06 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
US20040101915A1 (en) * 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
JP2007535324A (ja) * 2004-04-26 2007-12-06 チルドレンズ メディカル センター コーポレーション 疾患検出のための血小板バイオマーカー
MX2007001357A (es) * 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
EP2302388A1 (en) * 2004-10-14 2011-03-30 Genentech, Inc. COP1 molecules and uses thereof
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state

Also Published As

Publication number Publication date
JP2011511271A (ja) 2011-04-07
ES2453161T3 (es) 2014-04-04
AU2009206289A1 (en) 2009-07-30
EP2245460A1 (en) 2010-11-03
EP2708894A3 (en) 2014-04-02
EP2245460B1 (en) 2013-12-25
US10365279B2 (en) 2019-07-30
EP2245460A4 (en) 2011-05-25
EP2708894B1 (en) 2016-07-06
WO2009094619A1 (en) 2009-07-30
JP2017102125A (ja) 2017-06-08
KR20100131435A (ko) 2010-12-15
JP6087888B2 (ja) 2017-03-01
ES2589506T3 (es) 2016-11-14
KR20150123344A (ko) 2015-11-03
EP2708894A2 (en) 2014-03-19
US20110027811A1 (en) 2011-02-03
JP2015052605A (ja) 2015-03-19
KR101711860B1 (ko) 2017-03-03
KR101714359B1 (ko) 2017-03-09

Similar Documents

Publication Publication Date Title
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
HK1150401A1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
EP2046973A4 (en) METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
EP2111173A4 (en) TREATMENT SYSTEM AND TREATMENT DEVICE
IL213070A0 (en) Methods for the treatment of infections and tumors
EP1804917A4 (en) DYNAMIC TUMOR TREATMENT SYSTEM
EP2337535A4 (en) SYSTEMS, DEVICES AND METHODS FOR THE TREATMENT OF ACOUPHEN
EP2106243A4 (en) TREATMENT SYSTEM AND TREATMENT DEVICE
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
EP2043621A4 (en) TREATMENT OF CANCER BY MODULATION OF PROTEIN KINASE USING HEXAHYDRO-ISOALPHA ACIDS
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
AP2011005637A0 (en) Carbazole compounds and therapeutic uses of the compounds.
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
ZA201001262B (en) Interval therapy for the treatment of tinnitus
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
GB0807018D0 (en) Antibodies and treatment
EP2150281A4 (en) BIOLOGICAL SCAFFOLDS CONTAINING TENOCYTES AND TREATMENT USING THEM
EP1979006A4 (en) LIQUID TREATMENT SYSTEM
EP2207555A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
GB2457965B8 (en) Methods and systems for determining efficacy of medicaments.
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
IL226362A0 (en) compounds, and methods for treating cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180126